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ABSTRACT: 
 
Dysfunctional glutamatergic neurotransmission has been implicated in Autism 
Spectrum Disorder (ASD). However, relatively few studies have directly measured 
brain glutamate in ASD adults, or related variation in glutamate to clinical 
phenotype.To investigate brain glutamate levels in adults with an ASD, comparing 
these to healthy controls and also comparing results between individuals at different 
points on the spectrum of symptom severity.We recruited28 adults with ASD and 14 
matched healthy controls. Of those with ASD, 15 were as fulfilling ‘narrowly’ 
defined criteria for typical autism, while 13 met the ‘broader phenotype’.We 
measured the concentration of the combined glutamate & glutamine signal (Glx), and 
other key metabolites, using proton magnetic resonance spectroscopy ([1H]MRS) in 
two brain regions implicated in ASD - the basal ganglia (including the head of 
caudate and the anterior putamen) and the dorsolateral prefrontal cortex - as well as in 
a parietal cortex ‘control’ region. Individuals with ASD had a significant decrease 
(p<0.001) in concentration of Glx in the basal ganglia, and this was true in both the 
‘narrow’ and ‘broader’ phenotype. Also, within the ASD sample, reduced basal 
ganglia Glx was significantly correlated with increased impairment in social 
communication (p=0.013). In addition, there was a significant reduction in the 
concentration of other metabolites such as Cho, Cr and NAA in the basal ganglia. In 
the DLPFC, Cr and NAA were reduced(p<0.05), though Glx was not. There were no 
detectable differences in Glx, or any other metabolite, in the parietal lobe control 
region. There were no significant between group differences in age, gender, IQ, voxel 
composition or data quality.In conclusion,individuals across the spectrum of ASD 
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have regionally-specific abnormalities in subcortical glutamatergic neurotransmission 
that are associated with variation in social development. 
 
KEYWORDS: autism spectrum disorders; autism; glutamate; glutamine; [1H]MRS 
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Introduction 
 
Autism Spectrum Disorder (ASD) is characterised by deficits in social reciprocity, 
communication impairments, and restricted, repetitive interests and behaviours.1 
Recent research suggests an approximate prevalence of 0.6-1.5% in the general 
population.2 
 
At present, however, therapeutic options for ASD are limited because the 
pathophysiology of ASD is unclear, leading to a paucity of treatment targets for the 
core symptoms. Numerous studies have reported abnormalities in brain anatomy and 
function of ASD individuals (e.g. see 3, 4) but the underlying molecular basis of these 
differences is unknown. 
 
There is, however, emerging evidence suggesting that ASD may be associated with  
abnormalities in excitatory glutamate and inhibitory gamma-amino-butyric acid 
(GABA) neurotransmission.5 The balanced interaction between glutamate and GABA 
transmission is essential for regulating cognition,  learning, memory, and emotional 
behaviours. An imbalance between glutamate excitation and GABA inhibition, 
leading to hyper-excitation, has been linked to ASD.6, 7, 8 
 
There is also evidence for an association between ASD and genetic variation in the 
glutamatergic and GABAergic systems. For example, there are reports of associations 
between ASD and variants in genes coding for glutamate receptors9, 10 and glutamate 
transporter proteins,11 although not in all studies.12 Also, recent work in Fragile X 
Syndrome, the most common monogenetic syndrome associated with ASD, points to 
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the potential importance of metabotropic glutamate receptors (mGluR1) as possible 
treatment targets in ASD.13 
 
Unfortunately, it is not possible to quantify glutamate and GABA concentrations in 
postmortem studies, because they degrade rapidly after death. Progress can be made, 
however, as in vivo proton magnetic resonance spectroscopy ([1H]MRS) can be used 
to quantify a range of neural metabolites, including glutamate and its metabolic 
product glutamine (Glu+Gln – henceforth abbreviated Glx). 
 
There are six published [1H]MRS studies reporting on Glx in ASD.  Four investigated 
children. Of these, one reported a widespread decrease in cortical Glx;14 and another 
reported non-significant reduction in Glx in the left thalamic region.15 However, two 
other studies found no differences in any region studied: one investigated the frontal, 
temporal and parietal cortex and basal ganglia16 and the other the frontal cortex and 
basal ganglia.17 
 
Only two published [1H]MRS studies have measured Glx in adults with ASD. Page et 
al reported that adults with ASD had a significantly higher concentration of Glx than 
controls in the right amygdala-hippocampal complex.18 In contrast, Bernardi et al 
found significantly lower Glx in the right anterior cingulate cortex.19 
 
These prior investigations suggest that ASD individuals may have differences in brain 
Glx, but the results are inconsistent. Possible explanations for this mixed picture are 
that some of these studies investigated relatively small samples, and they examined 
different age groups and/or brain regions. Also, no study of adults has yet addressed 
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whether any of these putative differences are present across the behavioural spectrum 
(i.e. in both the ‘core’ disorder, and those with the ‘broader phenotype’). 
 
This is potentially of importance because while, in the past, autism was generally 
treated as a “categorical” diagnosis, it is now understood to likely cover a spectrum of 
severity. For example, the biological relatives of people with ASD often show an 
attenuated “broader phenotype” of mild social, cognitive and neurobiological 
abnormalities.20 
 
This clinical (and likely aetiological) heterogeneity has led some to suggest that we 
refer to “the autisms” rather than to “autism” and search for final common pathways 
through which various causative agents may lead to disorder.21 However, previous 
[1H]MRS studies of adults with ASD have treated all participants with ASD as a 
single group (although one study in children did not.22) Thus, it is unclear whether 
putative abnormalities in Glx are present across the spectrum i.e. whether they are a 
potential common pathway, and/or relate to particular core symptoms. 
 
Hence, in the current study, we used [1H]MRS to investigate differences in brain 
glutamate and other metabolites in adults with ASD. We compared controls to ASD 
people diagnosed with the narrow ‘core’ disorder, who scored above cut off on 
research diagnostic criteria, and those with a broader phenotype, who only met some 
of the criteria. 
 
We focused on regions previously implicated in ASD pathology and 
symptomatology: the basal ganglia and the dorsolateral prefrontal cortex (DLPFC). 
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For example, 1) anatomical and metabolic abnormalities have been reported in both of 
these interconnected areas in ASD;23, 24 2) the basal ganglia have been linked with 
social and emotional differences25 and compulsive and repetitive behaviours26 and 3) 
the DLPFC has been linked to deficits in executive function27 and theory of mind.28 
Hence, we also correlated [1H]MRS measures that differed significantly between 
groups with scores on the Autism Diagnostic Interview - Revised (ADI-R) interview.  
 
We also included a ‘control’ region, in the medial parietal lobe, which has not been 
linked to ASD and where no differences were seen in a previous [1H]MRS study.18 
 
. 
 
 
 
 
 
 
Page 10 of 34 
 
Methods 
 
Participants 
 
We recruited 42 adult participants: 28 individuals with ASD and 14 healthy controls 
matched for age, gender and IQ (see Table 1). All participants had an IQ above 65. 
We recruited only participants who reported being right handed, in order to avoid 
possible lateralization effects given our use of unilateral [1H]MRS voxels. 
 
The 28 participants in the ASD group were further divided into two subtypes on the 
basis of their symptom profile. 15 were diagnosed with the ‘narrowly defined 
phenotype’ of autism on the basis that they met Autism Diagnostic Interview - 
Revised (ADI-R) cut-off criteria in all three symptom domains and fulfilled the 
diagnostic criteria for childhood autism or Asperger’s syndrome according to the 
ICD-10 Research Classification of Mental and Behavioural Disorders1 (criteria F84.0 
and F84.5 respectively). The other 13 individuals were classed as having the ‘broader 
phenotype’ i.e. they did not meet the ADI-R cut-off in one domain (See Table 1) and 
fulfilled ICD-10 diagnostic criteria for Atypical Autism (F84.1). 
 
All individuals with ASD were recruited through London’s Maudsley Hospital 
Behavioural Genetics Clinic, a specialist diagnostic service.  
 
Potential participants were excluded if they had a comorbid psychiatric or medical 
disorder affecting brain development (e.g. epilepsy or psychosis), a history of head 
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injury, a genetic disorder associated with ASD e.g. tuberous sclerosis or Fragile X 
syndrome, or an IQ below 65. Participants with ASD suffering from anxiety or 
depressive disorders were not excluded, given the high frequency of these 
comorbidities in ASD. According to participant self-report, all participants were 
medication naïve at the time of scanning. 
 
All participants provided written informed consent. Ethical approval for this study 
was provided by South London and Maudsley/Institute of Psychiatry NHS Research 
Ethics Committee, study reference 1997/087. 
 
[1H]-Magnetic Resonance Spectroscopy Data Acquisition 
 
[1H]MRSdata were acquired on a 1.5T GE HDx MRI scanner (GE Medical Systems, 
Milwaukee, WI, USA) equipped with TwinSpeed gradients. 
 
The scanning protocol included a structural MRI scan, namely a 3D fast inversion-
recovery prepared gradient echo acquisition (number of slices = 146, slice thickness = 
1.2 mm, inversion time (TI) = 300 ms, repetition time (TR) = 11 ms, echo time (TE) = 
5 ms, field of view = 310 mm, flip angle = 18°, matrix = 256x160 over a 310 x 194 
mm field of view, giving 1.2x1.2x1.2 mm3 voxels). This structural MRI was used for 
the localization of the spectroscopy voxels in each participant.  
 
Single voxel [1H]MRS spectra were then acquired, using a point-resolved 
spectroscopy (PRESS) sequence. PRESS parameters were: repetition time (TR) = 
3000 ms, echo time (TE) = 30 ms. A Voxel Of Interest (VOI) was positioned in left 
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basal ganglia (20x20x15 mm3). This voxel included parts of the head of the caudate, 
the anterior putamen, and the internal capsule. VOIs were also positioned in left 
dorsolateral prefrontal cortex (16x24x20 mm3) and in left medial parietal lobe 
(20x20x20 mm3), using previously described methods.29 See Figure 1 for an 
illustration of the location of the voxels. 
 
Data Processing 
 
[1H]MRS spectra were processed using LCModel software version 6-1-0. LCModel 
uses a linear combination of model spectra of metabolite solutions in vitro to analyze 
the major resonances of in vivo spectra. In this case, a basis set of alanine, aspartate, 
creatine, gamma-aminobutyric acid (GABA), glutamine, glutamate, 
glycerophosphocholine, mI, lactate, NAA, N-acetyl-aspartylglutamate (NAAg), 
scyllo-inositol, and taurine, together with a baseline function were used for analysis. 
Each spectrum was reviewed to ensure adequate signal to noise ratio, as well as the 
absence of artefacts. Note that the NAA resonance at 2 ppm contains both NAA and 
NAAg; we report results here reflecting the combination of NAA + NAAg; we use 
the term NAA for brevity. 
 
 Calculation of Absolute Metabolite Concentrations 
 
Metabolite concentrations for NAA, Cr, Glx and Cho were calculated, in institutional 
units, as follows. The raw metabolite estimates (LCModel output) were first corrected 
by reference to calibration data from a phantom, containing an aqueous solution of 
known NAA concentration. One phantom [1H]MRS spectrum was acquired at the end 
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of each scanning session. The amplitude of the phantom NAA peak was used to 
derive a correction factor, by which all metabolite values for the scan were multiplied. 
 
Furthermore, partial volume effects (group differences in proportions of gray matter, 
white matter and cerebrospinal fluid, CSF, in the [1H]MRS voxels) are a potential 
confound in spectroscopy. This could be especially relevant to the present 
investigation, given previously reported volumetric differences between ASD 
individuals and controls e.g. in the basal ganglia.23, 26 
 
Therefore, to guard against such confounds, we determined the percentage of gray 
matter, white matter and CSF within each [1H]MRS voxel for each participant. We 
first segmented the T1-weighted structural MRI using an automated procedure, 
spm_segment, part of the Statistical Parametric Mapping software package (SPM2; 
http://spm.ion.ucl.ac.uk). 
 
The position of each individual [1H]MRS voxel relative to the corresponding 
structural was determined, using positional coordinates embedded in the raw spectra 
data files. The % grey, white, and CSF composition of each voxel was then calculated 
automatically using in-house software. Finally, all metabolite concentrations 
were corrected for the amount of cerebrospinal fluid (CSF) in the voxel - under the 
assumption that CSF only contains negligible quantities of the metabolites of interest 
– by multiplying values by an individual correction factor = 1 / (1-ProportionCSF), 
where ProportionCSFcould range from 0 to 1, calculated separately for each voxel 
from each participant. This was applied after correcting for phantom NAA values (see 
above). 
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In summary: Metabolitecorrected = Metaboliteraw* (PhantomNAAknown/ 
PhantomNAAobserved) * (1 / (1 – ProportionCSF)). 
 
Statistical analysis 
 
Age and IQ were compared using one-way analysis of variance (ANOVA) across the 
three groups (healthy control, broad ASD, narrow ASD). 
 
Differences in mean metabolite concentrations were calculated using a series of one-
way ANOVAs, with group as a between-subjects factor. One such ANOVA was 
performed for each of the four metabolites, in each of the three voxels, a total of 12 
ANOVAs. As this procedure involves multiple (12) comparisons, we applied a 
Bonferroni correction to guard against Type I errors. We report results both before 
and after this correction. 
 
Planned post-hoc independent sample t-tests were then applied, in metabolites where 
a significant between-group difference was found on the ANOVA, in order to 
evaluate differences between (a) narrow ASD and healthy controls, (b) broader ASD 
and healthy controls, and (c) between the two ASD groups (narrow vs. broad). 
 
We examined possible correlations between concentrations of metabolites that 
differed significantly from controls in these t-tests against ADI-R domain scores, 
across the whole combined ASD group, using Pearson product-moment correlation 
coefficients. 
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All analyses were performed using SPSS 15.0 software (SPSS Inc, Chicago, Ill). 
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Results 
Demographics (Table 1) 
 
Groups did not differ significantly in age, full scale IQ, verbal IQ or performance IQ. 
 
Tissue Composition and Data Quality: 
 
Groups did not differ significantly in mean voxel % grey matter, white matter, or CSF 
in any of the three voxels (Table 2). This is unsurprising since, although volumetric 
differences have been observed in ASD in the basal ganglia26 and cortex,30 these were 
of small magnitude, and would not be expected to materially affect composition of 
hand-placed voxels. 
 
To verify that the quality of the [1H]MRS data did not vary between groups, we 
compared the LCModel 6-1-0 Cramer-Rao Lower Bound (CRLB) estimate standard 
deviations for each metabolite in each voxel, using a one-way ANOVA across the 
three groups. This revealed no significant differences (all F(2,42)<2.8, all p>0.07.) 
See Figure 2 for an example [1H]MRS spectrum after model fitting. 
 
Finally, because of the potential risk of ‘drift’ in extended [1H]MRS investigations (in 
which metabolite estimates on the same scanner change over long periods of time), 
we compared the timings of scans across the 3 groups, in terms of days after the first 
scan of the series. This revealed no significant difference (one-way ANOVA 
F(2,44)=0.739, p=0.484). Scan date was also not correlated with the value of any 
metabolite in any voxel (all Pearson’s r<0.23, all p>0.13). 
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Metabolite Differences (Table 3). 
 
Basal Ganglia.  There was a significant group effect in every metabolite 
concentration we measured in this voxel (ANOVA). Two of these effects – Cr and 
Glx - survived conservative Bonferroni correction for multiple comparisons over all 
metabolites and voxels. Post-hoc independent sample t-tests showed that Glx 
concentrations were significantly lower in both the ‘restricted’ and ‘broader’ ASD 
phenotypes compared to controls (see Figure 3). Both Cr and NAA showed a similar 
pattern. Cho was also lower in both ASD groups as compared to controls, but this 
only reached statistical significance in the broader ASD phenotype. 
 
There were no significant differences between the two ASD subgroups in any 
metabolite concentration. 
 
To establish whether the finding of lower Glx remained significant after controlling 
for tissue composition and the other metabolite concentrations, we performed a 
univariate GLM covarying for basal ganglia grey/white matter, Cr, NAA, Cho, age 
and IQ. The findings remained significant (F=3.530, p<0.05). 
 
Dorsolateral Prefrontal Cortex. There was no significant effect of group for Glx or 
Cho. However, there were significant effects of Cr and NAA, although neither of 
these differences survived conservative Bonferroni correction. Post-hoc tests revealed 
that Cr was significantly lower in both ASD groups relative to healthy controls, 
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whereas NAA was significantly lower only in the ‘narrow’ ASD phenotype.   
However, there were no significant differences between the two ASD subgroups. 
 
Parietal Region. As predicted, no significant differences were found in any 
metabolite concentration between any of the groups, even before Bonferroni 
correction. 
 
Relationship to behavioural variables. 
Across the combined ASD group (both broader and narrow phenotype), lower basal 
ganglia concentration of Glx was significantly correlated with worse scores on the 
ADI-R Communication scale (i.e. more abnormal Glx concentrations were associated 
with greater communication impairment (r = -0.465, p = 0.013, n=28). See Figure 4. 
This correlation was specific to this metabolite and this symptom domain: no 
correlations were seen in other metabolites or domains. 
We further examined this association within each group separately.  There was no 
significant correlation in the narrowly defined autism group (r = -0.224, p = 0.422), 
but there was in those with the broader phenotype (r = -0.805, p = 0.001). 
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Discussion 
 
We found that adults with ASD have a significantly reduced glutamate/glutamine 
(Glx) concentration in the basal ganglia as compared with controls. Our preliminary 
evidence further suggests that that this reduction was 1) regionally specific i.e. there 
were no significant differences in the other cortical regions we examined; 2) a 
potential final common pathway in ASD, as it was present in both ‘narrow’ and 
‘broadly’ defined ASD; and 3) was associated with some aspects of clinical variation 
(social communication). 
 
We suggest that it is unlikely that our findings can be fully explained by potential 
confounds, such as differences in voxel tissue composition, age, IQ, or medication. 
There were no significant between group differences in voxel grey matter, white 
matter and cerebrospinal fluid and all metabolite values were corrected for 
cerebrospinal fluid %. Demographic variables such as age, gender, and IQ were not 
different between the groups, all participants were right handed, and all of the 
individuals we studied were psychotropic medication naïve according to self-report.  
 
This is the first [1H]MRS study to report on Glx in the basal ganglia of adults with 
ASD. Our finding of reduced Glx in the basal ganglia (predominantly, the lentiform 
nuclei) agrees with studies finding reductions of Glx in the cingulate cortex and the 
thalamus,19 but contrasts with our previous finding of increased Glx in the amygdala-
hippocampal cortex in adults with ASD.18 Also, similar to prior studies, we found no 
differences in parietal cortex.18 
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Taken together these results demonstrate that, rather than being a ‘global’ 
neurobiological abnormality, Glx changes seen in ASD are highly regionally specific, 
suggesting that the underlying neurobiological cause(s) are also localized. Reductions 
in Glx could result simply from a local reduced density of glutamatergic synapses and 
neurons, such as reduced storage capacity and turnover, but could also be the product 
of alterations in glutamate and glutamine metabolism.   
 
In neurons, glutamate is synthesized from glutamine via glutaminase, but after release 
in the synapse, glutamate is converted back into glutamine in glial cells, by glutamine 
synthetase. Glutamate is also converted to GABA by the neuronal enzyme glutamate 
decarboxylase (GAD).5 
 
Alterations in GAD expression could bea potential explanation for the fact that we 
observed reduced Glx in the basal ganglia. This hypothesis would also help to 
reconcile these results with the suggestion that individuals with ASD have an 
inhibitory signalling deficit and an increased ratio of excitatory glutamate to 
inhibitory GABA transmission.8, 31 It is possible that, while the Glx signal was 
reduced, the ratio between glutamate and GABA was still increased. Reduced 
glutamate would be expected to lead to a corresponding reduction in GABA 
synthesis, since glutamate is the precursor of GABA. If GAD activity were reduced, 
one would expect a lower GABA:Glx ratio.  
 
Unfortunately, there have not yet been any studies examining GAD expression in the 
basal ganglia in ASD, but studies of other brain regions have shown regionally-
specific differences associated with the disorder. For example GAD has been reported 
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to be decreased in cerebellar Purkinje cells,32 but increased in cerebellar 
interneurons,33 in ASD. 
 
A further possibility is that the observed differences in Glx are secondary to 
alterations in other neurotransmitter systems. For example, the basal ganglia are 
densely innervated by serotonergic projections which exert complex modulatory 
effects on glutamate and GABA release.34 We and others reported reduced density of 
cortical 5HT2A receptors and serotonin transporter in the cortex and midbrain 35, 36, 37 
although see,38 and the same pattern has been found in the parents of children with 
ASD.39 Further, some have reported that children with ASD have significant  
differences in serotonin synthesis.40 Hence, it could be that serotonergic abnormalities 
underlie the differences in Glx we observed - either indirectly via influences on 
neurodevelopment, or through direct action on glutamate metabolism. 
 
Also, in the context of previous findings, our results suggest that within ASD age may 
be an important moderator of both cortical and subcortical differences in brain Glx.  
Specifically, prior [1H]MRS studies in children with ASD reported widespread 
decreases in cortical Glx14 – but no differences in the basal ganglia.16, 17 This is the 
opposite of the pattern we observed in adults namely no differences in the cortical 
regions (DLPFC and parietal lobe), but a reduction in the basal ganglia. This is 
consistent with the idea of autism as a disorder of brain maturation.41 We were unable 
to address age effects directly, as the current study did not include children – but this 
is a focus of our ongoing studies. 
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The correlation between basal ganglia [Glx] and the severity of social communication 
impairments in ASD is consistent with the known involvement of this area in various 
aspects of language and communication. For example, functional imaging studies 
demonstrated that the caudate and putamen are involved in ‘higher level’ aspects of 
language, such as inferring the implied as opposed to literal meaning of sentences,42 
and resolving ambiguous sentences – functions that are characteristically impaired in 
ASD. This correlation was specific to the basal ganglia, however, with no significant 
correlation seen in the DLPFC, an area also known to be involved in communication 
and Theory of Mind.28 One explanation for this could be that alterations in 
neurotransmitters other than glutamate are responsible for DLPFC dysfunction in 
autism; serotonin is one possibility, since a previous study found that lower cortical 
5HT2A receptor binding is associated with communication impairments in ASD.37 
 
We are only able to report a correlation between ASD in adults (and in particular, 
Social Communication symptoms as measured by the ADI-R) and reduced basal 
ganglia Glx levels. Hence, we cannot be certain whether the differences in Glx are the 
cause of the ASD symptoms. It is possible that they represent a downstream effect of 
the symptoms if, for example, the lack of social interaction or high-level language use 
engaged in by people with ASD led, over time, to neuroplastic changes in cortico-
basal circuits. However, we do not believe that this can explain all our results, 
because the ADI is a measure childhood (developmental) symptoms in the first years 
of life. 
 
In addition to the findings related to glutamate, discussed above, we also observed 
reduced levels of choline (Cho), creatine (Cr) and N-acetylaspartate (NAA) in the 
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basal ganglia, and of Cr and NAA in the DLPFC, in individuals with ASD, although 
only the basal ganglia Cr difference survived conservative Bonferroni correction. The 
finding of reduced Cr and NAA in both the basal ganglia and in the DLPFC is 
consistent with previous [1]H-MRS studies in this area in ASD.14, 15, 22 However, we 
have previously29 reported increased NAA, Cr and Cho in the medial prefrontal 
cortex of adults with Asperger’s Syndrome, underlining that the differences seen are 
regionally specific. Also in line with prior work,18, 29 we did not observe any 
significant metabolite differences in the parietal cortex control region. This confirms 
that the effects observed in the basal ganglia and the DLPFC are regionally specific. 
 
As both Cr and NAA are involved in neuronal energy metabolism, our finding of 
local reductions in these metabolites in the basal ganglia and the DLPFC may indicate 
either metabolic dysfunction in these areas, or a reduced density of metabolically 
active neurons. If the latter, this may also explain the observed reduction in Cho in the 
basal ganglia (since this is a component of cell membranes). 
 
Another important implication of our finding of reduced Cr in ASD in the basal 
ganglia and DLPFC is that it may be invalid to express the concentration of 
metabolites such as NAA and Glx as ratios to Cr in the same voxel. This approach is 
commonly used in [1H]MRS studies,22, 43 as it is widely assumed that Cr is constant;  
our findings suggest the this is not true in adults with ASD. 
 
However, our study does have a number of limitations. We obtained [1H]MRSdata on 
a 1.5 Tesla MRI scanner. At 1.5T it is not possible to distinguish between the 
compounds which contribute to the “Glx” signal, i.e. glutamate and glutamine. Future 
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studies at 3 Tesla or higher are needed to distinguish these compounds but previous 
studies have cautiously attributed reductions in Glx to glutamate, as glutamate 
constitutes the most abundant central neurotransmitter.14, 15, 18 
 
Another limitation is that we only recruited people with a normal or above-normal IQ, 
and excluded those with a history of epilepsy or seizures. This served to increase the 
homogeneity of the sample and ensure that any differences observed were associated 
with symptoms of ASD per se, but it means that the results may not be representative 
of the entire ASD population, since many people with ASD also suffer from a below-
normal IQ and/or epilepsy.1 Future studies should examine this population. 
 
In summary, we found preliminary evidence that adults with ASD (both narrowly and 
broadly defined) have significant differences in brain glutamate and/or glutamine 
metabolism. This may be a final ‘common pathway’ in the disorder, and underpin 
some clinical symptoms. Further work is required to determine the cause(s) of this 
putative abnormality. 
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Figure and Table Captions: 
 
Figure 1 – Examples of the location of [1H]MRS voxels. Three voxels were 
positioned in A. left basal ganglia (20x20x15 mm3) to include the head of the caudate, 
putamen, and internal capsule, B. left dorsolateral prefrontal cortex (16x24x20 mm3), 
and C. left medial parietal lobe (20x20x20 mm3). 
Figure 2 - Example of an [1H]MRS spectrum showing LCModel 6-1-0 fit. 
Figure 3 - Individual Participant Data showing Basal Ganglia Glutamate and 
Glutamine (Glx) By Group. 
Figure 4 - Association between Basal Ganglia Glx and ADI-R Communication 
Subscale Score in Individuals with ASD. 
Table 1 - Participant Demographic and Clinical Characteristics. 
Table 2 - Voxel Tissue Composition of Grey Matter, White Matter, and Cerebrospinal 
Fluid (CSF). 
Table 3 - Metabolite Concentrations in Basal Ganglia (BG), Dorsolateral Prefrontal 
Cortex (DLPFC) and Parietal Cortex [1H[MRS Voxels, and Group Differences. 
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TABLES 
 
Table 1 - Participant Demographic and Clinical Characteristics 
 Narrow ASD 
Broader 
ASD 
Control F P 
Number 15 13 14 
Number 
female 
1 1 3 
n/a 
Age in years 29 (6.0) 27 (6.4) 34 (8.8) 2.86 0.07 
FSIQ 95 (13) 103 (16) 107 (21) 1.63 0.21 
VIQ 95 (16) 101 (20) 106 (19.0) 1.21 0.31 
PIQ 96 (19) 106 (12) 107 (21) 1.47 0.24 
ADI-R 
A domain 
16.5 (4.2) 8.7 (2.4) 
ADI-R 
B domain 
10.7 (2.4) 6.3 (2.6) 
ADI-R 
C domain 
3.9 (0.8) 1.8 (1.5) 
n/a 
HFA=High Functioning Autism, FSIQ = full-scale IQ, VIQ = verbal IQ, PIQ = 
performance IQ. Values are expressed as mean (standard deviation) unless otherwise 
indicated. ADI-R = Autism Diagnostic Interview - Revised. Domain A = Social 
interaction, Domain B = Communication, Domain C = Restricted & repetitive patterns 
of behaviour. Note: the healthy control group did not receive an ADI-R assessment. 
Therefore, there are no ADI-R scores for this group. 
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Table 2 - Voxel Tissue Composition of Grey Matter, White Matter, and Cerebrospinal Fluid 
(CSF) 
 
ANOVA 
Region Measure 
Narrow 
ASD 
SD 
Broader 
ASD 
SD Control SD 
F P 
 
Gray matter 
62.20% 12.94% 64.99% 6.01% 54.31% 16.49% 2.65 0.084 
White matter 35.68% 13.07% 33.04% 5.12% 43.84% 17.13% 2.73 0.078 
Basal 
Ganglia 
CSF 2.09% 1.45% 1.92% 1.57% 1.82% 1.66% 0.16 0.849 
 
Gray matter 
45.35% 14.48% 45.32% 14.01% 2.17% 14.37% 0.38 0.685 
 
White matter 
48.79% 17.57% 49.37% 16.70% 54.06% 17.34% 0.68 0.685 
DLPFC 
CSF 5.67% 4.03% 5.07% 3.39% 4.03% 3.58% 0.76 0.476 
 
Gray matter 
44.47% 7.94% 47.61% 7.62% 44.89% 6.33% 1.03 0.366 
 
White matter 
35.16% 14.10% 34.47% 11.98% 38.39% 11.43% 0.35 0.706 
Parietal 
lobe 
 
CSF 
19.34% 14.28% 15.75% 6.86% 16.09% 7.56% 0.48 0.625 
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Table 3 - Metabolite Concentrations in Basal Ganglia (BG), Dorsolateral Prefrontal Cortex 
(DLPFC) and Parietal Cortex [1H[MRS Voxels, and Group Differences. 
ANOVA Post-hoc t-tests - P Values(b) 
Region 
Metabolite 
(a) 
Narrow 
ASD 
Broader 
ASD 
Control 
F P 
Narrow 
ASD 
Vs 
Controls 
Broad 
ASD 
Vs 
Controls
Broad 
ASD  vs 
Narrow 
ASD 
 
Glx 
 
 
10.12 (1.14) 
 
 
 
10.43 
(1.26) 
 
 
 
12.34 (1.45) 
 
 
12.63 
 
<0.0001**
 
<0.001 
 
0.001 
 
0.25 
Cho 
1.205 (0.19) 
 
1.098 
(0.14) 
 
1.324 (0.19) 
 
5.83 0.006* 0.212 0.004 0.44 
Cr 
5.097 (0.65) 
 
5.323 
(0.53) 
 
6.435 (1.25) 
 
10.02 0.0003** <0.001 0.004 0.47 
Basal 
Ganglia 
 
NAA 
5.454 (0.81) 
 
5.486 
(0.42) 
 
6.458 (1.52) 
 
4.54 0.017* 0.030 0.045 0.32 
Glx 
7.492 (1.11) 
 
7.156 
(1.51) 
 
8.007 (1.42) 
 
1.36 0.27 - - 0.32 
DLPFC 
 
Cho 1.129 (0.21) 1.110 1.271 (0.27) 2.35 0.11 - - 0.93 
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 (0.16) 
 
 
Cr 
4.074 (0.48) 
 
4.021 
(0.49) 
 
4.602 (0.60) 
 
5.32 0.009* 0.027 0.017 0.64 
NAA 
5.954 (0.79) 
 
5.955 
(0.47) 
 
6.660 (0.95) 
 
4.07 0.025* 0.047 0.057 0.22 
Glx 
10.607 (2.79) 
 
9.790 
(1.65) 
 
11.028 (1.62)
 
1.31 0.28 - - 0.41 
Cho 1.112 (0.37) 
1.048 
(0.13) 
1.149 (0.25) 0.53 0.59 - - 0.524 
Cr 5.461 (1.42) 
5.140 
(0.81) 
5.382 (0.70) 0.39 0.68 - - 0.19 
Parietal 
 
 
NAA 7.998 (2.32) 
7.472 
(0.76) 
7.887 (1.06) 0.48 0.62 - - 0.31 
Note: a Data expressed as mean (SD).  bPost-hoc t-tests comparing ASD cases to controls were only performed when ANOVA 
was significant p<0.05 uncorrected.  *Significant at p=0.05 level before Bonferroni correction. **Significant at p=0.05 level, 
with Bonferroni correction over 12 comparisons i.e. uncorrected p<0.0047. 
